Nanobiotix S.A. (NASDAQ:NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 8:00 AM ET

Company Participants

Kate Mcneil - Senior Vice President, Investor Relations

Laurent Levy - Co-Founder & Chief Executive Officer

Bart Van Rhijn - Chief Financial Officer

Conference Call Participants

Mike DiFiore - Evercore

Clément Bassat - BNP Paribas

Kate Mcneil

Thank you, operator. Good afternoon and good morning, and welcome to Nanobiotix Conference Call to discuss our Third Quarter 2022 Financial and Operational results.

Joining me in the call today, are Laurent Levy, co-Founder and Chief Executive Officer, and Bart Van Rhijn, Chief Financial Officer. As a reminder, today's call is being webcast and will be available on our website for replay.

I would like to remind you, that this call will include forward-looking statements, which may include statements regarding the progress, success and timing of our ongoing and planned clinical trials collaborations, regulatory filings, data presentation, and future research and development efforts, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. They are subject to significant risks and uncertainties that could cause the company's actual results to differ materially from our current expectations.

Accordingly, you are cautioned not to place undue reliance on forward-looking statements. This review the full description of risk factors that can be found in the documents we filed with the AMF in France and SEC in the United States, including our most recent URD and 20-F, each of which are available in the Investor Relations section of our website, along with a press release issued yesterday highlighting our corporate and financial results for the period.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, Nanobiotix undertakes no obligation to update them to reflect subsequent events or future circumstances.

With that said, I'd like to turn the call over to around the Laurent. Laurent, please go ahead.

Laurent Levy

Thank you, Kate. I would like to welcome everyone participating to this call. As Kate mentioned, we've been releasing yesterday our third quarter operational and financial update.

I would like for this particular call to focus on our priority pathway, which is developing our product in head and neck cancer. As you know, we intend to build a franchise in head and neck cancer patients in order to bring this product into market with this indication and then expand it into other indications.